Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Hepatology International
Erschienen in: Hepatology International 3/2021

08.07.2021 | Guidelines

Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)

verfasst von: Akash Shukla, Ananta Shreshtha, Amar Mukund, Chhagan Bihari, C. E. Eapen, Guohong Han, Hemant Deshmukh, Ian Homer Y. Cua, Cosmas Rinaldi Adithya Lesmana, Mamun Al Meshtab, Masayoshi Kage, Roongruedee Chaiteeraki, Sombat Treeprasertsuk, Suprabhat Giri, Sundeep Punamiya, Valerie Paradis, Xingshun Qi, Yasuhiko Sugawara, Zaigham Abbas, Shiv Kumar Sarin

Erschienen in: Hepatology International | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Budd Chiari syndrome (BCS) is a diverse disease with regard to the site of obstruction, the predisposing thrombophilic disorders and clinical presentation across the Asia-Pacific region. The hepatic vein ostial stenosis and short segment thrombosis are common in some parts of Asia-Pacific region, while membranous obstruction of the vena cava is common in some and complete thrombosis of hepatic veins in others. Prevalence of myeloproliferative neoplasms and other thrombophilic disorders in BCS varies from region to region and with different sites of obstruction. This heterogeneity also raises several issues and dilemmas in evaluation and approach to management of a patient with BCS. The opportunity to recanalize hepatic vein in patients with hepatic vein ostial stenosis or inferior vena cava stenting or pasty among those membranous obstruction of the vena cava is a unique opportunity in the Asia–Pacific region to restore hepatic outflow closely mimicking physiology. In order to address these issues arising out of the diversity as well as the unique features in the region, the Asia Pacific Association for Study of Liver has formulated these guidelines for clinicians.
Literatur
1.
Budd G. On diseases of the liver. 1st ed. London: J. & A. Churchill, Ltd; 1845. p. 146.
2.
Chiari H. Ueber die selbststandige Phlebitis obliterans der Hauptstamme der Venae hepaticae als Todesursache. Beitr Path Anat. 1899;26:1–18.
3.
4.
Blakemore AH. Portacaval anastomosis. Surg Gynecol Obstet. 1948;87:277–279.PubMed
5.
6.
Ochs A, Sellinger M, et al. Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol. 1993;18:217–225.PubMedCrossRef
7.
Ludwig J, Hashimoto E, McGill DB, van Heerden JA. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc. 1990;65:51–55.PubMedCrossRef
8.
McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver. 2000;20:3–7.PubMedCrossRef
9.
McCuskey RS, Reilly FD. Hepatic microvasculature: dynamic structure and its regulation. Semin Liver Dis. 1993;13:1–12.PubMedCrossRef
10.
Terasaki M, Kitai T, Morimoto T, et al. Hemodynamics and hepatic energy metabolism in canine model of acute hepatic venous occlusion with mesocaval shunt. Eur Surg Res. 1994;26:19–27.PubMedCrossRef
11.
Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.PubMedCrossRef
12.
Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36:1067–1073.PubMedCrossRef
13.
Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology. 1991;13:650–655.PubMedCrossRef
14.
Rajani R, Melin T, Bjornsson E, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int. 2009;29:253–259.PubMedCrossRef
15.
Ageno W, Dentali F, Pomero F, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017;117:794–800.PubMedCrossRef
16.
Ollivier-Hourmand I, Allaire M, Goutte N, et al. The epidemiology of Budd-Chiari syndrome in France. Dig Liver Dis. 2018;50:931–937.PubMedCrossRef
17.
Li Y, De Stefano V, Li H, et al. Epidemiology of Budd-Chiari syndrome: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019;43:468–474.PubMedCrossRef
18.
Shalimar KA, Kedia S, Sharma H, Gamanagatti SR, Gulati GS, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment Pharmacol Ther. 2016;43:1154–1167.PubMedCrossRef
19.
Ding PX, Han XW, Liu C, et al. Long-term outcomes of individualized treatment strategy in treatment of type I Budd-Chiari syndrome in 456 patients. Liver Int. 2019;39:1577–1586.PubMedCrossRef
20.
Shrestha SM, Okuda K, Uchida T, Maharjan KG, Shrestha S, Joshi BL, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol. 1996;11:170–179.PubMedCrossRef
21.
Shukla A, Parikh H, Modi T, Abraham P, Kamble S, Majumder D, et al. Hepatic vein obstruction is the most common type of hepatic venous outflow obstruction regardless of socioeconomic status. Ann Gastroenterol. 2015;28:130–134.PubMedPubMedCentral
22.
Cheng D, Xu H, Lu ZJ, Hua R, Qiu H, Du H, et al. Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study. J Gastroenterol Hepatol. 2013;28:1061–1067.PubMedCrossRef
23.
Uskudar O, Akdogan M, Sasmaz N, Yilmaz S, Tola M, Sahin B. Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J Gastroenterol. 2008;14:2858–2862.PubMedPubMedCentralCrossRef
24.
De BK, Biswas PK, Sen S, Das D, De KK, Das U, et al. Management of the Budd-Chiari syndrome by balloon cavoplasty. Indian J Gastroenterol. 2001;20:151–154.PubMed
25.
Sakr M, Barakat E, Abdelhakam S, Dabbous H, Yousuf S, Shaker M, et al. Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study. World J Gastroenterol. 2011;17:4704–4710.PubMedPubMedCentralCrossRef
26.
Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167–175.PubMedCrossRef
27.
Harmanci O, Kav T, Peynircioglu B, Buyukasik Y, Sokmensuer C, Bayraktar Y. Long¬term follow¬up study in Budd-Chiari syndrome: single¬center experience in 22 years. J Clin Gastroenterol. 2013;47:706–712.PubMedCrossRef
28.
Nozari N, Vossoghinia H, Malekzadeh F, Kafami L, Mirheidari M, Malekzadeh R. Long-term outcome of Budd-Chiari syndrome: a single center experience. Middle East J Dig Dis. 2013;5:146–150.PubMedPubMedCentral
29.
Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106:1042–1047.PubMedCrossRef
30.
Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM. Budd-Chiari syndrome causing acute liver failure: a multi- center case series. Liver Transpl. 2017;23:135–142.PubMedPubMedCentralCrossRef
31.
Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore). 1994;73:21–36.CrossRef
32.
Shin N, Kim YH, Xu H, Shi HB, Zhang QQ, Colon Pons JP, et al. Redefining Budd-Chiari syndrome: a systematic review. World J Hepatol. 2016;8:691–702.PubMedPubMedCentralCrossRef
33.
Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Haagsma EB, Kuipers EJ, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol. 2006;101:83–90.PubMedCrossRef
34.
Valla DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction. Hepatol Int. 2018;12(Suppl 1):168–180.PubMedCrossRef
35.
Singh V, Sinha SK, Nain CK, Bambery P, Kaur U, Verma S, et al. Budd-Chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol. 2000;15:550–554.PubMedCrossRef
36.
Shukla A, Bhatt P, Gupta DK, Modi T, Patel J, Gupte A, et al. Budd-Chiari syndrome has different presentations and disease severity during adolescence. Hepatol Int. 2018;12:560–566.PubMedCrossRef
37.
Eapen CE, Mammen T, Moses V, Shyamkumar NK. Changing profile of Budd Chiari syndrome in India. Indian J Gastroenterol. 2007;26:77–81.PubMed
38.
Jain A, Dhore P, Meshram M, Bhatia S, Shukla A. Patients with Budd-Chiari syndrome have variable coagulation status on thromboelastography at diagnosis. J Clin Exp Hepatol. 2019;9:460–467.PubMedCrossRef
39.
Qi X, De Stefano V, Wang J, Bai M, Yang Z, Han G, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol. 2013;28:432–442.PubMedCrossRef
40.
Mo A, Testro A, French J, Robertson M, Angus P, Grigg A. Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome. Intern Med J. 2017;47:1361–1367.PubMedCrossRef
41.
Derman BA, Kwaan HC. Risk factors, diagnosis, management, and outcome of splanchnic vein thrombosis: a retrospective analysis. Semin Thromb Hemost. 2015;41:503–513.PubMedCrossRef
42.
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatol Baltim Md. 2006;44:1528–1534.CrossRef
43.
Kiladjian J-J, Cervantes F, Leebeek FWG, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–4929.PubMedCrossRef
44.
Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162:730–747.PubMedCrossRef
45.
Westbrook RH, Lea NC, Mohamedali AM, Smith AE, Orr DW, Roberts LN, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc. 2012;18:819–827.
46.
Li X-M, Wei Y-F, Hao H-L, Hao Y-B, He L-S, Li J-D, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol. 2002;71:11–14.PubMedCrossRef
47.
Qi X, Han G, Guo X, De Stefano V, Xu K, Lu Z, et al. Review article: the aetiology of primary Budd-Chiari syndrome—differences between the West and China. Aliment Pharmacol Ther. 2016;44:1152–1167.PubMedCrossRef
48.
Wang H, Sun G, Zhang P, Zhang J, Gui E, Zu M, et al. JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients. J Gastroenterol Hepatol. 2014;29:208–214.PubMedCrossRef
49.
Qi X, Wu F, Ren W, He C, Yin Z, Niu J, et al. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 2013;109:878–884.PubMedCrossRef
50.
Parkash O, Khan A, Hamid S. Clinical characteristics and outcome of Budd-Chiari syndrome at a tertiary care hospital in Pakistan. J Coll Phys Surg-Pak JCPSP. 2017;27:301–304.
51.
Tasneem AA, Soomro GB, Abbas Z, Luck NH, Hassan SM. Clinical presentation and predictors of survival in patients with Budd Chiari syndrome: experience from a tertiary care hospital in Pakistan. JPMA J Pak Med Assoc. 2015;65:120–124.PubMed
52.
Poisson J, Plessier A, Kiladjian J-J, Turon F, Cassinat B, Andreoli A, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. 2017;67:501–507.PubMedCrossRef
53.
Turon F, Cervantes F, Colomer D, Baiges A, Hernández-Gea V, Garcia-Pagán JC. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol. 2015;62:72–74.PubMedCrossRef
54.
Jain A, Tibdewal P, Shukla A. Calreticulin mutations and their importance in Budd-Chiari syndrome. J Hepatol. 2017;67:1111–1112.PubMedCrossRef
55.
Jain A, Shetty S, Kulkarni B, Ghosh K. Association of factor VII gene polymorphisms with Budd Chiari syndrome. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2010;21:296–297.CrossRef
56.
Kathuria R, Srivastava A, Yachha SK, Poddar U, Baijal SS. Budd-Chiari syndrome in children: clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014;26:1030–1038.PubMedCrossRef
57.
Sharma VK, Ranade PR, Marar S, Nabi F, Nagral A. Long-term clinical outcome of Budd-Chiari syndrome in children after radiological intervention. Eur J Gastroenterol Hepatol. 2016;28:567–575.PubMedCrossRef
58.
Singh SK, Sen Sarma M, Yadav R, Kumar S, Prasad R, Yachha SK, et al. Prognostic scoring systems and outcome of endovascular radiological intervention of chronic Budd-Chiari syndrome in children. Liver Int. 2018;38:1308–1315.PubMedCrossRef
59.
Nagral A, Hasija RP, Marar S, et al. Budd-Chiari syndrome in children: experience with therapeutic radiological intervention. J Pediatr Gastroenterol Nutr. 2010;50:74–78.PubMedCrossRef
60.
De BK, De KK, Sen S, Biswas PK, Das TK, Das S, et al. Etiology based prevalence of Budd-Chiari syndrome in eastern India. J Assoc Phys India. 2000;48:800–803.
61.
Rathod K, Deshmukh H, Shukla A, Popat B, Pandey A, Gupte A, et al. Endovascular treatment of Budd-Chiari syndrome: single center experience. J Gastroenterol Hepatol. 2017;32:237–243.PubMedCrossRef
62.
Faraoun SA, Boudjella MEA, Debzi N, Benidir N, Afredj N, Guerrache Y, et al. Budd-Chiari syndrome: an update on imaging features. Clin Imaging. 2016;40:637–646.PubMedCrossRef
63.
Liu S-Y, Xiao P, Cao H-C, Jiang H-S, Li T-X. Accuracy of computed tomographic angiography in the diagnosis of patients with inferior vena cava partial obstruction in Budd-Chiari syndrome. J Gastroenterol Hepatol. 2016;31:1933–1939.PubMedCrossRef
64.
Miller WJ, Federle MP, Straub WH, Davis PL. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging. 1993;18:329–335.PubMedCrossRef
65.
Richard G, Mark L. Textbook of gastrointestinal radiology, 4th ed. 2015. p. 1682–1686.
66.
DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764.PubMedCrossRef
67.
Boozari B, Bahr MJ, Kubicka S, Klempnauer J, Manns MP, Gebel M. Ultrasonography in patients with Budd-Chiari syndrome—diagnostic signs and prognostic implications. J Hepatol. 2008;49:572–580.PubMedCrossRef
68.
Federle MP, Raman SP. Diagnostic imaging gastrointestinal, 3rd ed. 2015. p. 711.
69.
Garcia-Pagán JC, Buscarini E, Janssen HLA, Leebeek FWG, Plessier A, Rubbia-Brandt L, et al. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.CrossRef
70.
Mamone G, Carollo V, Di Piazza A, Cortis K, Degiorgio S, Miraglia R. Budd-Chiari Syndrome and hepatic regenerative nodules: magnetic resonance findings with emphasis of hepatobiliary phase. Eur J Radiol. 2019;117:15–25.PubMedCrossRef
71.
Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–89.PubMedCrossRef
72.
Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol. 2003;39:496–501.PubMedCrossRef
73.
Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39:500–508.PubMedCrossRef
74.
Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–815.PubMedCrossRef
75.
Rautou PE, Moucari R, Escolano S, Cazals-Hatem D, Denié C, Chagneau-Derrode C, et al. Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104:1140–1146.PubMedCrossRef
76.
Zhang K, Xu H, Zu M, Wei N. Predictive value of five prognostic models for Budd-Chiari syndrome in China (Article in Chinese). Nan Fang Yi Ke Da Xue Xue Bao. 2014;34:3488–3491.
77.
Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatol Baltim Md. 1995;21:1238–1247.
78.
Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatol Baltim Md. 1998;27:488–496.CrossRef
79.
De Sousa JM, Portmann B, Williams R. Nodular regenerative hyperplasia of the liver and the Budd-Chiari syndrome. Case report, review of the literature and reappraisal of pathogenesis. J Hepatol. 1991;12:28–35.PubMedCrossRef
80.
Zhou H, Wolff M, Pauleit D, Fischer HP, Pfeifer U. Multiple macroregenerative nodules in liver cirrhosis due to Budd-Chiari syndrome. Case reports and review of the literature. Hepatogastroenterology. 2000;47:522–527.PubMed
81.
Cazals-Hatem D, Vilgrain V, Genin P, Denninger M-H, Durand F, Belghiti J, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatol Baltim Md. 2003;37:510–519.CrossRef
82.
Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR Am J Roentgenol. 2002;178:877–883.PubMedCrossRef
83.
Gwon D, Ko G-Y, Yoon H-K, Sung K-B, Kim JH, Lee SS, et al. Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE. Radiology. 2010;254:617–626.PubMedCrossRef
84.
Vilgrain V, Lewin M, Vons C, Denys A, Valla D, Flejou JF, et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology. 1999;210:443–450.PubMedCrossRef
85.
Zhang R, Qin S, Zhou Y, Song Y, Sun L. Comparison of imaging characteristics between hepatic benign regenerative nodules and hepatocellular carcinomas associated with Budd-Chiari syndrome by contrast enhanced ultrasound. Eur J Radiol. 2012;81:2984–2989.PubMedCrossRef
86.
Maetani Y, Itoh K, Egawa H, Haga H, Sakurai T, Nishida N, et al. Benign hepatic nodules in Budd-Chiari syndrome: radiologic-pathologic correlation with emphasis on the central scar. AJR Am J Roentgenol. 2002;178:869–875.PubMedCrossRef
87.
88.
Zucman-Rossi J, Jeannot E, Nhieu JTV, Scoazec J-Y, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatol Baltim Md. 2006;43:515–524.CrossRef
89.
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc J-F, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152:880–894.PubMedCrossRef
90.
Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatol Baltim Md. 2016;64:2047–2061.CrossRef
91.
Sempoux C, Paradis V, Komuta M, Wee A, Calderaro J, Balabaud C, et al. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. J Hepatol. 2015;63:1173–1180.PubMedCrossRef
92.
Ibarrola C, Castellano VM, Colina F. Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction: a clinicopathological study of four patients and 24 nodules. Histopathology. 2004;44:172–179.PubMedCrossRef
93.
Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:830–841.PubMedCrossRef
94.
Moucari R, Rautou P-E, Cazals-Hatem D, Geara A, Bureau C, Consigny Y, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008;57:828–835.PubMedCrossRef
95.
Sakr M, Abdelhakam SM, Dabbous H, Hamed A, Hefny Z, Abdelmoaty W, et al. Characteristics of hepatocellular carcinoma in Egyptian patients with primary Budd-Chiari syndrome. Liver Int Off J Int Assoc Study Liver. 2017;37:415–422.
96.
Paul SB, Shalimar SV, Gamanagatti SR, Sharma H, Dhamija E, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction. Aliment Pharmacol Ther. 2015;41:961–971.PubMedCrossRef
97.
Oliveira EC, Duarte AG, Boin IF, Almeida JR, Escanhoela CA. Large benign hepatocellular nodules in cirrhosis due to chronic venous outflow obstruction: diagnostic confusion with hepatocellular carcinoma. Transplant Proc. 2010;42:4116–4118.PubMedCrossRef
98.
Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P. Hepatocellular nodules in vascular liver diseases. Virchows Arch Int J Pathol. 2018;473:33–44.CrossRef
99.
Vilgrain V, Paradis V, Van Wettere M, Valla D, Ronot M, Rautou P-E. Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdom Radiol N Y. 2018;43:1968–1977.CrossRef
100.
Van Wettere M, Purcell Y, Bruno O, Payancé A, Plessier A, Rautou P-E, et al. Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. J Hepatol. 2019;70:1123–1132.PubMedCrossRef
101.
Suri A, Sharma VK, Ranade PR, Marar S, Nagral A. Ruptured hepatocellular carcinoma in a child with Budd-Chiari syndrome. Indian Pediatr. 2016;53:833–883.PubMedCrossRef
102.
Shin SH, Chung YH, Suh DD, Shin JW, Jang MK, Ryu SH, et al. Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004;16:319–24.PubMedCrossRef
103.
Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(1182–1188):e1.
104.
Miller ZA, Lee KS. Screening for hepatocellular carcinoma in high-risk populations. Clin Imaging. 2016;40:311–314.PubMedCrossRef
105.
Park H, Yoon JY, Park KH, Kimdo Y, Ahn SH, Han KH, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea. World J Gastroenterol. 2012;18:1946–1952.PubMedPubMedCentralCrossRef
106.
Dang X, Li L, Li S, Wang Y, Li H, Xu S, et al. Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction. Int J Clin Exp Med. 2015;8:9071–9078.PubMedPubMedCentral
107.
Wang Y, Xue H, Jiang Q, Li K, Tian Y. Multiple hyperplastic nodular lesions of the liver in the Budd-Chari syndrome: a case report and review of published reports. Ann Saudi Med. 2015;35:72–75.PubMedPubMedCentralCrossRef
108.
Van Wettere M, Paulatto L, Raynaud L, et al. Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Rep. 2020;2:100097.PubMedPubMedCentralCrossRef
109.
Liovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.CrossRef
110.
Wang YD, Xue HZ, Zhang X, et al. Clinical and pathological features and surgical treatment of Budd-Chiari syndrome associated hepatocellular carcinoma. Chin Med J (Engl). 2013;126:3632–3638.
111.
Dang X, Li L, Li L, Li S, Xu P. Clinical and pathological comparison of Budd-Chiari syndrome associated hepatocellular carcinoma and HBV-associated hepatocellular carcinoma. Int J Clin Exp Med. 2016;9(12):23173–23181.
112.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–116.PubMedCrossRef
113.
Liu FY, Wang MQ, Duan F, et al. Hepatocellular carcinoma associated with budd-chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol. 2013;13:105.PubMedPubMedCentralCrossRef
114.
Dou JP, Yu J, Han ZY, Liu FY, Cheng ZG, Liang P. Microwave ablation for hepatocellular carcinoma associated with Budd-Chiari syndrome after transarterial chemoembolization: an analysis of ten cases. Abdom Radiol (NY). 2017;42(3):962–968.CrossRef
115.
Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari SYNDROME: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520.PubMedCrossRef
116.
Ulrich F, Pratschke J, Neumann U, Pascher A, Puhl G, Fellmer P, Weiss S, Jonas S, Neuhaus P. Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. Liver Transpl. 2008;14(2):144–150.PubMedCrossRef
117.
Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002;74:1090–1095.PubMedCrossRef
118.
Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger M-H, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44:1308–1316.PubMedCrossRef
119.
Seijo S, Plessier A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–1968.PubMedCrossRef
120.
Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS ONE. 2012;7:e44064.PubMedPubMedCentralCrossRef
121.
Shukla A, Jain A, Kahalekar V, Bendkhale S, Gogtay N, Thatte U, et al. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin. Hepatol Int. 2019;13:214–221.PubMedCrossRef
122.
De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699.PubMedCrossRef
123.
Sharma S, Kumar R, Rout G, Gamanagatti SR, Shalimar. Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention. J Gastroenterol Hepatol. 2020;35:654–662.PubMedCrossRef
124.
European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver. J Hepatol. 2016;64:179–202.CrossRef
125.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352.CrossRefPubMed
126.
Rautou PE, Douarin L, Denninger MH, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol. 2011;54:56–63.PubMedCrossRef
127.
Zaman S, Wiebe S, Bernal W, et al. Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis. Eur J Gastroenterol Hepatol. 2016;28:967–971.PubMedCrossRef
128.
Shetty S, Kulkarni B, Pai N, et al. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–85.PubMedCrossRef
129.
Liakoni E, Rätz Bravo AE, Terracciano L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Int Med. 2014;174:1683–1686.CrossRef
130.
Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation. 2011;92:341–345.PubMedCrossRef
131.
Chagneau-Derrode C, Roy L, Guilhot J, et al. Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepato-splanchnic vein thrombosis. Hepatology. 2013;58:857A.
132.
Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92:187–195.PubMedCrossRef
133.
van Bijnen STA, van Rijn RS, Koljenovic S, et al. Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. Br J Haematol. 2012;157:762–763.PubMedCrossRef
134.
MacNicholas R, Olliff S, Elias E, et al. An update on the diagnosis and management of Budd-Chiari syndrome. Expert Rev Gastroenterol Hepatols. 2012;6:731–744.CrossRef
135.
Hernández-Guerra M, López E, Bellot P, et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology. 2006;43:27–33.PubMedCrossRef
136.
Meng X, Lv Y, Zhang B, He C, Guo W, Luo B, et al. Endovascular management of Budd-Chiari Syndrome with inferior vena cava thrombosis: a 14-year single-center retrospective report of 55 patients. J Vasc Interv Radiol. 2016;27:1592–1603.PubMedCrossRef
137.
Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004;40:172–180.PubMedCrossRef
138.
Smalberg JH, Spaander MV, Jie KS, et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost. 2008;100:1084–1088.PubMedCrossRef
139.
Valla DC. Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut. 2008;57:1469–1478.PubMedCrossRef
140.
Han G, Qi X, Zhang W, He C, Yin Z, Wang J, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013;266:657–667.PubMedCrossRef
141.
Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut. 2006;55:878–884.PubMedPubMedCentralCrossRef
142.
Zhang F, Wang C, Li Y. The outcomes of interventional treatment for Budd-Chiari syndrome: systematic review and meta-analysis. Abdom Imaging. 2015;40:601–608.PubMedCrossRef
143.
144.
Wang Q, Li K, He C, Yuan X, Luo B, Qi X, et al. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomized controlled trial. Lancet Gastroenterol Hepatol. 2019;4:686–697.PubMedCrossRef
145.
Cui YF, Fu YF, Li DC, Xu H. Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival. Hepatol Int. 2016;10:363–369.PubMedCrossRef
146.
Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int. 2017;37:111–120.PubMedCrossRef
147.
Qi X, Guo W, He C, Zhang W, Wu F, Yin Z, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int. 2014;34:1164–1175.PubMedCrossRef
148.
Mancuso A. Budd-chiari syndrome management: timing of treatment is an open issue. Hepatology. 2014;59:1213.PubMedCrossRef
149.
Rosenqvist K, Sheikhi R, Eriksson LG, Rajani R, Rorsman F, Sangfelt P, et al. Endovascular treatment of symptomatic Budd-Chiari syndrome—in favour of early transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol. 2016;28:656–660.PubMedCrossRef
150.
Hayek G, Ronot M, Plessier A, Sibert A, Abdel-Rehim M, Zappa M, et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd-Chiari syndrome. Radiology. 2017;283:280–292.PubMedCrossRef
151.
Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114:1296–1303.PubMedCrossRef
152.
Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–1202.PubMedCrossRef
153.
Gandini R, Konda D, Simonetti G. Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents. Radiology. 2006;241:298–305.PubMedCrossRef
154.
Darwish Murad S, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. Liver Int. 2008;28:249–256.PubMedCrossRef
155.
Tripathi D, Macnicholas R, Kothari C, Sunderraj L, Al-Hilou H, Rangarajan B, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther. 2014;39:864–872.PubMedCrossRef
156.
Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–475.PubMedCrossRef
157.
Khan F, Armstrong MJ, Mehrzad H, et al. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. Aliment Pharmacol Ther. 2019;49:840–863.PubMedCrossRef
158.
Panis Y, Belghiti J, Valla D, et al. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery. 1994;115:276–281.PubMed
159.
Hemming AW, Langer B, Greig P, et al. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg. 1996;171:176–180.PubMedCrossRef
160.
Bachet JB, Condat B, Hagege H, Plessier A, Consigny Y, Belghiti J, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol. 2007;46:60–68.PubMedCrossRef
161.
Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007;13:1285–1294.PubMedCrossRef
162.
Knoop M, Lemmens HP, Langrehr JM, et al. Liver transplantation for Budd-Chiari syndrome. Transpl Proc. 1994;26:3577–3578.
163.
Attwell A, Ludkowski M, Nash R, et al. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment Pharmacol Ther. 2004;20:867–873.PubMedCrossRef
164.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.CrossRefPubMed
165.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.PubMedCrossRef
166.
Sakr M, Abdelhakam SM, Elsayed SA, et al. Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: a single-center study. World J Gastroenterol. 2017;23:629–637.PubMedPubMedCentralCrossRef
167.
Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther. 2009;30:1060–1069.PubMedCrossRef
168.
Darwish Murad S, Kim WR, de Groen PC, et al. Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome? Liver Transpl. 2007;13:867–874.PubMedCrossRef
169.
Zahn A, Gotthardt D, Weiss KH, Richter G, Schmidt J, Stremmel W, et al. Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt. BMC Gastroenterol. 2010;10:25.PubMedPubMedCentralCrossRef
170.
171.
Mancuso A. An update on the management of Budd-Chiari syndrome: the issues of timing and choice of treatment. Eur J Gastroenterol Hepatol. 2015;27:200–203.PubMedCrossRef
172.
Khan F, Mehrzad H, Tripathi D. Timing of transjugular intrahepatic portosystemic stent-shunt in Budd-Chiari syndrome: A UK Hepatologist’s Perspective. J Transl Int Med. 2018;6:97–104.PubMedPubMedCentralCrossRef
173.
Sun Y, Ma X, Feng L, Guan S, Wang Z. Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome. Gut. 2012;61:1779–1780.PubMedCrossRef
174.
Qi X, Yang M, Fan D, Han G. Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: a critical review of literatures. Scand J Gastroenterol. 2013;48:771–784.PubMedCrossRef
175.
Sonavane AD, Amarapurkar DN, Rathod KR, Punamiya SJ. Long-term survival of patients undergoing TIPS in Budd-Chiari syndrome. J Clin Exp Hepatol. 2019;9:56–61.PubMedCrossRef
176.
Gupta P, Bansal V, Kumar MP, Sinha SK, Samanta J, Mandavdhare H, et al. Diagnostic accuracy of Doppler ultrasound, CT and MRI in Budd Chiari syndrome: systematic review and meta-analysis. Br J Radiol. 2020;93:20190847.PubMedPubMedCentralCrossRef
177.
Boyer TD, Haskal ZJ. American Association for the Study of Liver Disease. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400.PubMedCrossRef
178.
Shukla A, Bhatt P, Gupta DK, Modi T, Patel J, Phadke M, et al. Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver. Indian J Gastroenterol. 2017;36:474–480.PubMedCrossRef
179.
Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions -Part II: Recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30:1168–1184.PubMedCrossRef
180.
Chana A, James M, Veale P. Anaesthesia for transjugular intrahepatic portosystemic shunt insertion. BJA Education. 2016;16:405–409.CrossRef
181.
Punamiya S, Tesdal K, Dettmer S. Transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome and portal vein thrombosis (Chapter 5.6.2). Vascular Interventions. Stuttgart: Georg Thieme Verlag; 2016. p. 347–354.
182.
Soares GM, Murphy TP. Transcaval TIPS: indications and anatomic considerations. J Vasc Interv Radiol. 2006;29:857–861.
183.
Hatzidakis A, Galanakis N, Kehagias E, et al. Ultrasound-guided direct intrahepatic portosystemic shunt in patients with Budd-Chiari syndrome: short- and long-term results. Interv Med Appl Sci. 2017;9:86–93.PubMedPubMedCentral
184.
Farsad K, Fuss C, Kolbeck KJ, Barton RE, Lakin PC, Keller FS, et al. Transjugular intrahepatic portosystemic shunt creating using intravascular ultrasound guidance. J Vasc Interv Radiol. 2012;23:1594–1602.PubMedCrossRef
185.
Boyvat F, Harman A, Ozyer U, Aytekin C, Arat Z. Percutaneous sonographic guidance for TIPS in Budd-Chiari syndrome: direct simultaneous puncture of the portal vein and inferior vena cava. AJR Am J Roentgenol. 2008;191:560–564.PubMedCrossRef
186.
Punamiya SJ, Pant R, Amarapurkar DN, Irani FG, Shah SR. Usefulness of TIPS in Budd-Chiari syndrome. J Vasc Interv Radiol. 2004;15:S154–156.
187.
Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics. 2009;29:669–681.PubMedCrossRef
188.
Murad SD, Valla DC, de Greon PC, Zeitoun G, Haagsma EB, Kuipers EJ, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroeneterol. 2006;101:83–90.CrossRef
189.
LaBerge JM, Ring EJ, Lake JR, Ferrell LD, Doherty MM, Gordon RL, et al. Transjugular intrahepatic portosystemic shunts: preliminary results in 25 patients. J Vasc Surg. 1992;16:258–267.PubMedCrossRef
190.
Cejna M, Peck-Radosavljevic M, Schoder M, Thurnher S, Ba-Ssalamah A, Angermayr B, et al. Repeat interventions for maintenance of transjugular intrahepatic portosystemic shunt function in patients with Budd-Chiari syndrome. J Vasc Interv Radiol. 2002;13:193–199.PubMedCrossRef
191.
Rossle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery. 2004;135:394–403.PubMedCrossRef
192.
Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–285.PubMedPubMedCentralCrossRef
193.
Corso R, Intotero M, Solcia M, Castoldi MC, Rampoldi A. Treatment of Budd-Chiari syndrome with transjugular intrahepatic portosystemic shunt (TIPS). Radiol Med. 2008;113:727–738.PubMedCrossRef
194.
Saad WEA, Darwish WM, Davies MG, Waldman DL. Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialised TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol. 2010;21:1512–1520.PubMedCrossRef
195.
Luo XF, Nie L, Wang Z, Tsauo J, Liu LJ, Yu Y, et al. Stent-grafts for the treatment of TIPS dysfunction: fluency stent vs Wallgraft stent. World J Gastroenterol. 2013;19:5000–5005.PubMedPubMedCentralCrossRef
196.
Fitsiori K, Tsitskari M, Kelekis A, Filippiadis D, Triantafyllou K, Brountzos E. Transjugular intrahepatic portosystemic shunt for the treatment of Budd-Chiari syndrome patients: results from a single center. Cardiovasc Intervent Radiol. 2014;37:691–697.PubMedCrossRef
197.
Spiliopoulos S, Lalenis C, Konstantos C, Palialiexis K, Tsitskari M, Reppas L, et al. Long-term efficacy of transjugular intrahepatic portosystemic shunt treatment for Budd-Chiari Syndrome. Hell J Radiol. 2017;2:12–19.
198.
Fan X, Liu K, Che Y, Wang S, Wu X, Cao J, et al. Good clinical outcomes in Budd-Chiari syndrome with hepatic vein occlusion. Dig Dis Sci. 2016;61:3054–3060.PubMedCrossRef
199.
He F, Zhao H, Dai S, Wu Y, Wang L, Huang H, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome with diffuse occlusion of hepatic veins. Sci Rep. 2016;6:36380.PubMedPubMedCentralCrossRef
200.
Bi Y, Chen H, Ding P, Zhou P, Han X, Ren J. Excellent long-term outcomes of endovascular treatment in Budd-Chiari syndrome with hepatic veins involvement: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e12944.CrossRef
201.
Neumann AB, Andersen SD, Nielsen DT, Holland-Fischer P, Vilstrup H, Grønbæk H. Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. World J Hepatol. 2013;5:38–42.PubMedPubMedCentralCrossRef
202.
Shalimar GSR, Patel AH, Kedia S, Nayak B, Gunjan D, et al. Long-term outcomes of transjugular intrahepatic portosystemic shunt in Indian patients with Budd-Chiari syndrome. Eur J Gastroenterol Hepatol. 2017;29:1174–1182.PubMedCrossRef
203.
Mancuso A, Fung K, Mela M, Tibballs J, Watkinson A, Burroughs AK, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol. 2003;38:751–754.PubMedCrossRef
204.
Blum U, Rössle M, Haag K, Ochs A, Blum HE, Hauenstein KH, et al. Budd-Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology. 1995;197:805–811.PubMedCrossRef
205.
Perelló A, García-Pagán JC, Gilabert R, Suárez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–139.PubMedCrossRef
206.
Casadaban LC, Parvinian A, Couture PM, Minocha J, Knuttinen MG, Bui JT, et al. Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality. AJR Am J Roentgenol. 2014;203:1363–1370.PubMedCrossRef
207.
Chung HH, Razavi MK, Sze DY, Frisoli JK, Kee ST, Dake MD, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications? J Gastroenterol Hepatol. 2008;23:95–101.PubMedCrossRef
208.
Wolf DC, Siddiqui S, Rayyan Y, Rozenblit G. Emergent stent occlusion for TIPS-induced liver failure. Dig Dis Sci. 2005;50(12):2356–2358.PubMedCrossRef
209.
Huang Q, Shen B, Zhang Q, Xu H, Zu M, Gu Y, et al. Comparison of long-term outcomes of endovascular management for membranous and segmental inferior vena cava obstruction in patients with primary Budd-Chiari Syndrome. Circ Cardiovasc Interv. 2016;9:e003104.PubMedCrossRef
210.
Zhang QQ, Xu H, Zu MH, Zu MH, Gu YM, Shen B, et al. Strategy and long-term outcomes of endovascular treatment for Budd-Chiari syndrome complicated by inferior vena caval thrombosis. Eur J Vasc Endovasc Surg. 2014;47:550–557.PubMedCrossRef
211.
Fu YF, Li Y, Cui YF, Wei N, Li DC, Xu H. Percutaneous recanalization for combined-type Budd-Chiari syndrome: strategy and long-term outcome. Abdom Imaging. 2015;40:3240–3247.PubMedCrossRef
212.
Cheng DL, Xu H, Li CL, Lv WF, Li CT, Mukhiya G, et al. Interventional treatment strategy for primary budd-chiari syndrome with both inferior vena cava and hepatic vein involvement: patients from two centers in China. Cardiovasc Intervent Radiol. 2019;42:1311–1321.PubMedCrossRef
213.
214.
Mukund A, Mittal K, Mondal A, Sarin SK. Anatomic recanalization of hepatic vein and inferior vena cava versus direct intrahepatic portosystemic shunt creation in Budd-Chiari Syndrome: overall outcome and midterm transplant-free survival. J Vasc Interv Radiol. 2018;29:790–799.PubMedCrossRef
215.
Cheng DL, Zhu N, Xu H, Li CL, Lv WF, Fang WW, et al. Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction. Exp Ther Med. 2018;16:4141–4149.PubMedPubMedCentral
216.
Gao Y, Chen S, Yu C. Applicability of different endovascular methods for treatment of refractory Budd-Chiari syndrome. Cell Biochem Biophys. 2011;61:453–460.PubMedCrossRef
217.
Chen ZK, Fan J, Cao C, Li Y. Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome. Radiol Med. 2018;123:799–807.PubMedCrossRef
218.
Fu YF, Xu H, Zhang K, Zhang QQ, Wei N. Accessory hepatic vein recanalization for treatment of Budd-Chiari syndrome due to long-segment obstruction of the hepatic vein: initial clinical experience. Diagn Interv Radiol. 2015;21:148–153.PubMedPubMedCentralCrossRef
219.
Cui YF, Fu YF, Wei N, Zhu HC, Xu H. Retrograde puncture assisted hepatic vein recanalization in treating Budd-Chiari syndrome with segmental obstruction of hepatic vein. Radiol Med. 2015;120:1184–1189.PubMedCrossRef
220.
Zhang CQ, Fu LN, Xu L, Zhang GQ, Jia T, Liu JY, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol. 2003;9:2587–2591.PubMedPubMedCentralCrossRef
221.
Yang XL, Cheng TO, Chen CR. Successful treatment by percutaneous balloon angioplasty of Budd-Chiari syndrome caused by membranous obstruction of inferior vena cava: 8-year follow-up study. J Am Coll Cardiol. 1996;28:1720–1724.PubMedCrossRef
222.
Ding PX, Zhang SJ, Li Z, Fu MT, Hua ZH, Zhang WG. Long-term safety and outcome of percutaneous transhepatic venous balloon angioplasty for Budd-Chiari syndrome. J Gastroenterol Hepatol. 2016;31:222–228.PubMedCrossRef
223.
Mukund A, Gamanagatti S, Acharya SK. Radiological interventions in HVOTO–practical tips. Trop Gastroenterol. 2011;32:4–14.PubMed
224.
Li WD, Yu HY, Qian AM, Rong JJ, Zhang YQ, Li XQ. Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: a retrospective analysis of a large cohort. Eur Radiol. 2017;27:1227–1237.PubMedCrossRef
225.
Zhang W, Tian YL, Wang QZ, Chen XW, Li QY, Han JH, et al. Restenosis after recanalization for Budd-Chiari syndrome: management and long-term results of 60 patients. World J Clin Cases. 2020;8:2930–2941.PubMedPubMedCentralCrossRef
226.
Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology. 2003;38:793–803.PubMedCrossRef
227.
Kew MC, Hodkinson HJ. Membranous obstruction of inferior vena cava and its causal relation to hepatocellular carcinoma. Liver Int. 2006;26:1–7.PubMedCrossRef
228.
Kage M, Arakawa M, Kojiro M, Okuda K. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology. 1992;102:2081–2090.PubMedCrossRef
229.
Okuda K. Membranous obstruction of the inferior vena cava (Obliterative hepatocavopathy Okuda). J Gastroenterol Hepatol. 2001;16:1179–1183.PubMedCrossRef
230.
Shrestha SM, Kage M, Lee BB. Hepatic vena cava syndrome: new concept of pathogenesis. Hepatol Res. 2017;47:603–615.PubMedCrossRef
231.
Shrestha SM. Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava. Hepatol Int. 2009;3:392–402.PubMedPubMedCentralCrossRef
232.
De Franchis R. Evolving consensus in portal hypertension, Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167–176.PubMedCrossRef
233.
Mukund A, Pargewar SS, Desai SN, Rajesh S, Sarin SK. Changes in liver congestion in patients with budd-chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–687.PubMedCrossRef
234.
Shukla A, Bhatia SJ. Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. Indian J Gastroenterol. 2010;29:8–11.PubMedCrossRef
235.
Jagtap N, Sharma M, Singh J, Tandan M, Rao PN, Gupta R, et al. Budd-Chiari syndrome: outcomes of endovascular intervention—a single-center experience. Indian J Gastroenterol. 2017;36:209–216.PubMedCrossRef
236.
Dajti E, Ravaioli F, Colecchia A, Marasco G, Vestito A, Festi D. Liver and spleen stiffness measurements for assessment of portal hypertension severity in patients with budd chiari syndrome. Can J Gastroenterol Hepatol. 2019;2019:1673197.PubMedPubMedCentralCrossRef
237.
Wang HK, Lai YC, Tseng HS, Lee RC, Loong CC, Lin NC, et al. Hepatic venous congestion after living donor liver transplantation: quantitative assessment of liver stiffness using shear wave elastography—a case report. Transplant Proc. 2012;44:814–816.PubMedCrossRef
238.
Song J, Ma Z, Huang J, Liu S, Luo Y, Lu Q, et al. Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. Eur Radiol. 2018;28:5221–5230.PubMedCrossRef
239.
Wang HW, Shi HN, Cheng J, Xie F, Luo YK, Tang J. Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: a pilot study. PLoS ONE. 2018;13:e0197550.PubMedPubMedCentralCrossRef
240.
Xu P, Lyu L, Ge H, Sami MU, Liu P, Hu C, et al. Segmental liver stiffness evaluated with magnetic resonance elastography is responsive to endovascular intervention in patients with Budd-Chiari syndrome. Korean J Radiol. 2019;20:773–780.PubMedPubMedCentralCrossRef
241.
Wagner M, Corcuera-Solano I, Lo G, Esses S, Liao J, Besa C, et al. Technical failure of MR elastography examinations of the liver: experience from a large single-center study. Radiology. 2017;284:401–412.PubMedCrossRef
242.
Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–371.PubMedCrossRef
243.
Masudanayagam R, Shanmugam V, Gunson B, Mirza DF, Mayer D, Buckels J, et al. Etiology and outcomes of acute liver failure. HPB (Oxford). 2009;11:429–434.
244.
Parekh J, Matei VM, Canas-Colo A, Friedman D, Lee WM, Acute Liver Failure Study Group. Budd Chiari Syndrome causing acute liver failure: a multicenter case series. Liver Transpl. 2017;23:135–142.PubMedPubMedCentralCrossRef
245.
Sarin SK, Kedarisetty CK, Abbas Z, et al. APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2014;8:453–471.PubMedCrossRef
246.
Shalimar SS, Gamanagatti SR, Chauhan A, Vuyyuru SK, Elhence A, et al. Acute-on-chronic liver failure in budd-chiari syndrome: profile and predictors of outcome. Dig Dis Sci. 2020;65:2719–2729.PubMedCrossRef
247.
Shukla A, Jain A. Association of acute-on-chronic liver failure with vascular liver diseases. Hepatol Int. 2019;13:399–402.PubMedCrossRef
248.
Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med. 1980;68:113–121.PubMedCrossRef
249.
Rautou PE, Plessier A, Bernuau J, Denninger MH, Moucari R, Valla D. Pregnancy: a risk factor for Budd-Chiari syndrome? Gut. 2009;58:606–608.PubMedCrossRef
250.
Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology. 2001;34:666–670.PubMedCrossRef
251.
Shukla A, Sadalage A, Gupta D, Gupte A, Mahapatra A, Mazumder D, et al. Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment. Liver Int. 2018;38:754–759.PubMedCrossRef
252.
Rautou P-E, Angermayr B, Garcia-Pagan J-C, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54.PubMedCrossRef
253.
Hüttel E, Padberg S, Meister R, Beck E, Schaefer C. Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Thromb Haemost. 2017;117:870–879.PubMedCrossRef
254.
Simon EG, Joseph AJ, George B, Zachariah UG, Jeyamani R, Eapen CE, et al. Aetiology of paediatric portal hypertension—experience of a tertiary care centre in South India. Trop Doct. 2009;39:42–44.PubMedCrossRef
255.
Poddar U, Thapa BR, Rao KL, Singh K. Etiological spectrum of esophageal varices due to portal hypertension in Indian children: is it different from the West? J Gastroenterol Hepatol. 2008;23:1354–1357.PubMedCrossRef
256.
Gili K, Ulrike N-G. Venous thromboembolism in neonates and children. Best Pract Res Clin Haematol. 2012;25:333–344.CrossRef
257.
Alam S, Khanna R, Mukund A. Clinical and prothrombotic profile of hepatic vein outflow tract obstruction. Indian J Pediatr. 2014;81:434–440.PubMedCrossRef
Metadaten
Titel
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)
verfasst von
Akash Shukla
Ananta Shreshtha
Amar Mukund
Chhagan Bihari
C. E. Eapen
Guohong Han
Hemant Deshmukh
Ian Homer Y. Cua
Cosmas Rinaldi Adithya Lesmana
Mamun Al Meshtab
Masayoshi Kage
Roongruedee Chaiteeraki
Sombat Treeprasertsuk
Suprabhat Giri
Sundeep Punamiya
Valerie Paradis
Xingshun Qi
Yasuhiko Sugawara
Zaigham Abbas
Shiv Kumar Sarin
Publikationsdatum
08.07.2021
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 3/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10189-4

Weitere Artikel der Ausgabe 3/2021

Hepatology International 3/2021 Zur Ausgabe

Original Article

Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study

Editorial

A community of portal hypertension

Original Article

Human fascioliasis presenting as liver abscess: clinical characteristics and management

Original Article

Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm

Original Article

Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study

Original Article

A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise